Bauerschlag Dirk O, Schem Christian, Baumann Klaus, Harter Philip, Hilpert Felix, Wagner Uwe, du Bois Andreas, Pfisterer Jakobus
Department of Gynecology and Obstetrics, University Clinic Schleswig-Holstein, Campus Kiel, Michaelisstrasse 16, 24105 Kiel, Germany.
Future Oncol. 2008 Dec;4(6):769-73. doi: 10.2217/14796694.4.6.769.
Ovarian cancer is the fifth most common malignancy with approximately 22,000 newly diagnosed cases each year in the USA. Standard of care after cytoreductive surgery is the application of carboplatin and paclitaxel. The newly developed anti-idiotypic monoclonal antibody abagovomab demonstrated promising results in Phase I/II trials. This new type of drug is currently being tested in a Phase II/III trial in ovarian cancer patients with a complete response after standard first-line chemotherapy. Activating the cancer hosts immune system is a new strategy that is worth being pursued in the fight against ovarian cancer.
卵巢癌是美国第五大常见恶性肿瘤，每年约有22,000例新诊断病例。细胞减灭术后的标准治疗是应用卡铂和紫杉醇。新开发的抗独特型单克隆抗体阿巴伏单抗在I/II期试验中显示出有前景的结果。这种新型药物目前正在对标准一线化疗后完全缓解的卵巢癌患者进行II/III期试验。激活癌症宿主的免疫系统是在抗击卵巢癌中值得追求的新策略。
